BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

Last update: 08 Dec, 2025, 12:49PM

52.10

-0.05 (-0.10%)

  • 1D -0.10%
  • 5D -8.15%
  • 1M -4.68%
  • 6M 11.59%
  • YTD -2.54%
  • 1Y -8.66%
  • 5Y -18.82%
Previous Close 52.15
Open 52.20
Volume 5,219,922
Avg. Volume (3M) 16,324,425
Market Cap 106,062,733,312
Price / Earnings (TTM) 17.54
Price / Earnings (Forward) 9.13
Price / Sales 2.34
Price / Book 6.06
52 Weeks Range
42.52 (-18%) — 63.33 (21%)
Earnings Date 30 Oct 2025
TTM Dividend Yield 1.19%
Profit Margin 11.38%
Operating Margin (TTM) 31.57%
Diluted EPS (TTM) 2.68
Quarterly Revenue Growth (YOY) -5.60%
Quarterly Earnings Growth (YOY) -95.90%
Total Debt/Equity (MRQ) 293.85%
Current Ratio (MRQ) 1.28
Operating Cash Flow (TTM) 14.31 B
Levered Free Cash Flow (TTM) 13.93 B
Return on Assets (TTM) 7.24%
Return on Equity (TTM) 31.99%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Mixed
Drug Manufacturers - General (Global) Mixed Mixed
Stock Bristol-Myers Squibb Company Bullish Bearish

AIStockmoo Score

1.1
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -1.0
Technical Moving Averages 0.0
Technical Oscillators 4.0
Average 1.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
BMY 106 B 1.19% 17.54 6.06
JNJ 526 B 0.57% 21.10 6.65
ABBV 394 B 1.47% 169.09 50.46
MRK 273 B 0.74% 14.46 5.31
PFE 145 B 1.69% 14.84 1.57
GSK 102 B 1.62% 14.06 4.50

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.07%
% Held by Institutions 82.11%
52 Weeks Range
42.52 (-18%) — 63.33 (21%)
Price Target Range
37.00 (-28%) — 65.00 (24%)
High 65.00 (UBS, 24.76%) Buy
Median 60.00 (15.16%)
Low 37.00 (Morgan Stanley, -28.98%) Sell
Average 56.67 (8.77%)
Total 4 Buy, 4 Hold, 1 Sell
Avg. Price @ Call 53.75
Firm Date Target Price Call Price @ Call
Leerink Partners 13 Jan 2026 60.00 (15.16%) Buy 55.92
Scotiabank 09 Jan 2026 60.00 (15.16%) Hold 55.86
04 Dec 2025 53.00 (1.73%) Hold 51.95
Citigroup 07 Jan 2026 53.00 (1.73%) Hold 56.72
17 Nov 2025 45.00 (-13.63%) Hold 46.81
UBS 07 Jan 2026 65.00 (24.76%) Buy 56.72
B of A Securities 15 Dec 2025 61.00 (17.08%) Buy 54.29
Guggenheim 12 Dec 2025 62.00 (19.00%) Buy 52.41
Morgan Stanley 12 Dec 2025 37.00 (-28.98%) Sell 52.41
Wells Fargo 10 Dec 2025 55.00 (5.57%) Hold 51.21
Goldman Sachs 02 Dec 2025 57.00 (9.40%) Hold 48.25
Show more

No data within this time range.

  • 3M
Date Type Details
20 Jan 2026 CNBC Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
12 Jan 2026 Announcement Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
02 Jan 2026 Announcement Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference
19 Dec 2025 CNBC Nine of the largest pharma companies ink deals with Trump to lower drug prices
19 Dec 2025 Announcement Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
18 Dec 2025 Announcement Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
11 Dec 2025 Announcement U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
10 Dec 2025 Announcement Bristol Myers Squibb Announces Dividend Increase
08 Dec 2025 Announcement Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
04 Dec 2025 Announcement Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
03 Dec 2025 Announcement Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
03 Dec 2025 Announcement Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
01 Dec 2025 Announcement Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
26 Nov 2025 Announcement Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
24 Nov 2025 Announcement Bristol Myers Squibb to Host Hematology-Focused Investor Event
24 Nov 2025 Announcement Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
18 Nov 2025 Announcement Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
17 Nov 2025 Announcement Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
14 Nov 2025 Announcement Update on Phase 3 Librexia ACS Trial
12 Nov 2025 Announcement Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
05 Nov 2025 Announcement Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
03 Nov 2025 Announcement Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
03 Nov 2025 Announcement Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
30 Oct 2025 Announcement Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
27 Oct 2025 Announcement Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
25 Oct 2025 Announcement Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
Show more
TTM Dividend Yield 1.19%
5Y Average Dividend Yield 3.20%
Payout Ratio 91.04%
Ex Date Announcement Date Payment Date Details
03 Jan 2025 11 Dec 2024 03 Feb 2025 0.62 Cash
04 Oct 2024 10 Sep 2024 01 Nov 2024 0.6 Cash
05 Jul 2024 18 Jun 2024 01 Aug 2024 0.6 Cash
04 Apr 2024 01 Mar 2024 01 May 2024 0.6 Cash
04 Jan 2024 06 Dec 2023 01 Feb 2024 0.6 Cash
05 Oct 2023 20 Sep 2023 01 Nov 2023 0.57 Cash
06 Jul 2023 14 Jun 2023 01 Aug 2023 0.57 Cash
06 Apr 2023 03 Mar 2023 01 May 2023 0.57 Cash
05 Jan 2023 08 Dec 2022 01 Feb 2023 0.57 Cash
06 Oct 2022 14 Sep 2022 01 Nov 2022 0.54 Cash
30 Jun 2022 15 Jun 2022 01 Aug 2022 0.54 Cash
31 Mar 2022 01 Mar 2022 02 May 2022 0.54 Cash
06 Jan 2022 13 Dec 2021 01 Feb 2022 0.54 Cash
30 Sep 2021 09 Sep 2021 01 Nov 2021 0.49 Cash
01 Jul 2021 17 Jun 2021 02 Aug 2021 0.49 Cash
31 Mar 2021 01 Mar 2021 03 May 2021 0.49 Cash
31 Dec 2020 10 Dec 2020 01 Feb 2021 0.49 Cash
01 Oct 2020 10 Sep 2020 02 Nov 2020 0.45 Cash
02 Jul 2020 11 Jun 2020 03 Aug 2020 0.45 Cash
02 Apr 2020 02 Mar 2020 01 May 2020 0.45 Cash
02 Jan 2020 06 Dec 2019 03 Feb 2020 0.45 Cash
03 Oct 2019 12 Sep 2019 01 Nov 2019 0.41 Cash
03 Jul 2019 14 Jun 2019 01 Aug 2019 0.41 Cash
04 Apr 2019 08 Mar 2019 01 May 2019 0.41 Cash
03 Jan 2019 07 Dec 2018 01 Feb 2019 0.41 Cash
04 Oct 2018 13 Sep 2018 01 Nov 2018 0.4 Cash
05 Jul 2018 15 Jun 2018 01 Aug 2018 0.4 Cash
05 Apr 2018 01 Mar 2018 01 May 2018 0.4 Cash
04 Jan 2018 07 Dec 2017 01 Feb 2018 0.4 Cash
05 Oct 2017 13 Sep 2017 01 Nov 2017 0.39 Cash
05 Jul 2017 13 Jun 2017 01 Aug 2017 0.39 Cash
05 Apr 2017 02 Mar 2017 01 May 2017 0.39 Cash
04 Jan 2017 08 Dec 2016 01 Feb 2017 0.39 Cash
05 Oct 2016 03 Aug 2016 01 Nov 2016 0.38 Cash
29 Jun 2016 07 Jun 2016 01 Aug 2016 0.38 Cash
30 Mar 2016 03 Mar 2016 02 May 2016 0.38 Cash
30 Dec 2015 08 Dec 2015 01 Feb 2016 0.38 Cash
30 Sep 2015 17 Sep 2015 02 Nov 2015 0.37 Cash
01 Jul 2015 16 Jun 2015 03 Aug 2015 0.37 Cash
01 Apr 2015 02 Mar 2015 01 May 2015 0.37 Cash
30 Dec 2014 09 Dec 2014 02 Feb 2015 0.37 Cash
01 Oct 2014 16 Sep 2014 03 Nov 2014 0.36 Cash
01 Jul 2014 17 Jun 2014 01 Aug 2014 0.36 Cash
02 Apr 2014 03 Mar 2014 01 May 2014 0.36 Cash
31 Dec 2013 19 Dec 2013 03 Feb 2014 0.36 Cash
02 Oct 2013 17 Sep 2013 01 Nov 2013 0.35 Cash
02 Jul 2013 19 Jun 2013 01 Aug 2013 0.35 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 0.620 1 1.15
2024 2.40 4 4.24
2023 2.28 4 4.44
2022 2.16 4 3.00
2021 1.96 4 3.14
2020 1.80 4 2.90
2019 1.64 4 2.56
2018 1.60 4 3.08
2017 1.56 4 2.55
2016 1.52 4 2.60
2015 1.48 4 2.15
2014 1.44 4 2.44
2013 0.700 2 1.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria